Yuhan Corporation

Abl Bio Inc.

Young Bong Park

Eun-Jung Lee

Moo Young Song

Na Rae Lee

Yangsoon Lee

Hyejin Chung

Kyeongsu Park

Ui-Jung Jung

Yeryoung Yong

Wonjun Son

Sunghyun Choi

June Hyung Lee

Ju Young Park

Ki Hong Kim

Jong-Seo Lee

Eunyoung Park

Eunsil Sung

Yeunju Kim

Youngdon Pak

Byung Hyun Choi

Donghoon Yeom

Yong-Gyu Son

Jaehyun Eom

Seawon Ahn

Minji Park

Eunjung Kim

Taewang Kim

Kyu-Tae Kim

Bong-Kook Ko

Eunjeong Jeong

YoungKwang Kim

Hyoju Choi

Kwang-Hoon Lee

Nakho Chang

Chanmoo Lee

Junghyeon Hong

Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-HER2/anti-4-1BB bispecific antibody and use thereof

Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-EGFR/anti-4-1BB bispecific antibody

Disclosed are a novel antibody specifically binding to the tumor-immunosuppressant, TIGIT (T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif [ITIM] domain) or an antigen-binding fragment thereof, a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector and a host cell including the nucleic acid, a method for producing the antibody or the antigen-binding fragment thereof, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof as an active ingredient, and uses of the pharmaceutical composition. The antibody specifically binding to TIGIT or the antigen-binding fragment thereof and the pharmaceutical composition containing the same as an active ingredient are preferably used for the treatment of cancer or tumors.

Anti-TIGIT antibodies and uses thereof

Growing community of inventors

Yongin-si, South Korea

Young Bong Park